Trust Signals
Written by the FormBlends Medical Team. All dose figures are sourced from the peer-reviewed Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) and ClinicalTrials.gov registrations. No dose is fabricated. Where Phase 3 data are not yet public, that limitation is stated explicitly. This page does not constitute medical advice.
Key Takeaways
- The Phase 2 trial tested 1 mg, 4 mg, 8 mg, and 12 mg once-weekly subcutaneous doses; the 12 mg arm used a 20-week step-up escalation before reaching maintenance.
- Mean body weight reduction at 48 weeks was approximately 24.2% in the highest-dose (12 mg) group, based on Jastreboff et al. 2023 in NEJM.
- Retatrutide is a triple receptor agonist (GLP-1, GIP, glucagon); the glucagon component is the pharmacological distinction from tirzepatide and is also its main theoretical risk for heart rate elevation.
- Retatrutide is not FDA-approved as of mid-2026; Phase 3 TRIUMPH trials are ongoing and approval timelines remain speculative.
- GI adverse events (nausea, vomiting, diarrhea) were dose-dependent and drove most discontinuations in the higher-dose arms.
What Is the Retatrutide Clinical Trial Dose?
The pivotal Phase 2 trial of retatrutide tested once-weekly subcutaneous injections at 1 mg, 4 mg, 8 mg, and 12 mg in adults with obesity. The three higher-dose arms used structured step-up escalation lasting roughly 12 to 20 weeks before reaching the target maintenance dose. The 12 mg arm achieved mean weight loss of approximately 24.2% over 48 weeks. No single dose has been approved; these are research doses only.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Phase 2 trial design and exact dose arms
- Escalation schedules: what the protocol actually specified
- Mechanism with numbers: how three receptors drive greater weight loss
- Evidence ledger table
- What most pages get wrong about retatrutide dosing
- Honest head-to-head: retatrutide vs. tirzepatide vs. semaglutide
- Safety profile and discontinuation data
- Operational literacy: how to read a retatrutide COA or trial listing
- Phase 3 TRIUMPH program: what is known
- FAQ
- Sources
What Did the Phase 2 Trial Actually Test?
Jastreboff et al. published the double-blind, randomized, placebo-controlled Phase 2 trial in the New England Journal of Medicine in June 2023. The trial enrolled 338 adults with a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity) without type 2 diabetes. Participants were randomized to:
- Placebo once weekly
- 1 mg retatrutide once weekly (flat dose, no escalation)
- 4 mg retatrutide once weekly (with escalation)
- 8 mg retatrutide once weekly (with escalation)
- 12 mg retatrutide once weekly (with escalation)
Duration was 48 weeks of treatment plus a follow-up period. All participants received dietary and lifestyle counseling. This was a single Phase 2 study; it was not powered to detect rare adverse events and the sample sizes per arm were modest (roughly 60 to 70 participants per active arm).
What Did the Escalation Schedule Look Like?
The step-up design is critical because applying a maintenance dose without escalation would dramatically worsen GI tolerability. The Phase 2 protocol (as reported in the NEJM publication and supplementary data) used the following approximate structure:
| Target Dose | Starting Dose | Escalation Steps | Approximate Weeks to Maintenance |
|---|---|---|---|
| 1 mg | 1 mg | None | 0 (flat) |
| 4 mg | 2 mg | 2 mg for 4 weeks, then 4 mg | ~4 |
| 8 mg | 2 mg | 2 mg / 4 mg / 8 mg stepwise | ~12 |
| 12 mg | 2 mg | 2 mg / 4 mg / 8 mg / 12 mg stepwise | ~20 |
How Does Targeting Three Receptors Change the Dose-Response Math?
Retatrutide is a single peptide molecule engineered to activate three G-protein-coupled receptors with meaningful potency at each:
- GLP-1 receptor (GLP-1R): Slows gastric emptying, increases satiety signaling in the hypothalamus, augments glucose-dependent insulin secretion. This is the mechanism shared with semaglutide and tirzepatide.
- GIP receptor (GIPR): Augments insulin secretion and, at brain GIPR, modulates food reward. This is the second component shared with tirzepatide.
- Glucagon receptor (GCGR): Increases resting energy expenditure through hepatic and thermogenic mechanisms, promotes lipolysis, and raises hepatic glucose output. This is the component unique to retatrutide among approved or late-stage obesity drugs.
The glucagon component is why retatrutide trials also measured heart rate: glucagon receptor agonism raises pulse. In the Phase 2 trial, the 12 mg arm showed a mean increase in heart rate of approximately 4 beats per minute compared to placebo. That is a clinically relevant signal in a population at cardiovascular risk, though it is smaller than the historical signal from pure glucagon infusion because the GLP-1 component partially offsets cardiac stimulation. This interaction is a real pharmacodynamic trade-off, not a resolved problem.
The glucagon agonism also explains why retatrutide reduced liver fat to a greater degree than would be expected from weight loss alone in mechanistic substudies, an observation consistent with the known role of glucagon in hepatic lipid metabolism. However, this does not confirm clinical benefit for MASLD (metabolic dysfunction-associated steatotic liver disease) without dedicated outcomes trials.
Evidence Ledger: What Does Each Major Claim Actually Rest On?
| Claim | Best Evidence Type | Source | Effect Direction | Confidence |
|---|---|---|---|---|
| ~24.2% weight loss at 48 weeks, 12 mg arm | Phase 2 RCT (n~65 in arm) | Jastreboff et al., NEJM 2023 | Large benefit vs. placebo (~2.1%) | Moderate |
| GI adverse events are dose-dependent | Phase 2 RCT | Jastreboff et al., NEJM 2023 | Higher dose = more nausea/vomiting | High |
| Heart rate increase ~4 bpm at 12 mg | Phase 2 RCT | Jastreboff et al., NEJM 2023 | Modest increase | Moderate |
| Glucagon agonism raises energy expenditure | Mechanistic / animal studies | Multiple preclinical studies | Directional increase | Low (for humans) |
| Retatrutide reduces liver fat beyond weight loss | Phase 2 substudy (imaging) | Jastreboff et al., NEJM 2023 supplementary | Favorable direction | Low (small n, no outcomes) |
| Superior to semaglutide/tirzepatide on weight loss | Cross-trial comparison only | No head-to-head RCT exists | Appears favorable but unconfirmed | Very Low |
| Phase 3 TRIUMPH will confirm Phase 2 results | Assumption / trial registration | ClinicalTrials.gov | Unknown | Very Low |
What Most Pages Get Wrong About Retatrutide Dosing
Nearly every article presenting retatrutide doses treats the Phase 2 escalation schedule as if it were a prescription template. Three things are wrong with that framing:
1. Phase 2 doses are not validated maintenance doses. Phase 2 trials find a signal and explore tolerability. They do not determine the optimal dose for a broad population. The Phase 3 TRIUMPH program will likely test a narrower dose range with larger samples, and the approved dose (if approval happens) may differ from anything used in Phase 2.
2. The compound in circulation is not the trial compound. The retatrutide used in Eli Lilly's trials was pharmaceutical-grade material manufactured under current Good Manufacturing Practice, with verified peptide sequence, purity above 98%, and endotoxin testing. Peptides sold outside that system, including through research chemical vendors, are not equivalent. No compounding pharmacy can legally compound a drug that is not FDA-approved; retatrutide currently falls outside the categories that allow compounding under 503A or 503B.
3. The escalation schedule is a safety tool, not a formality. The slow step-up exists because GLP-1 receptor agonism at doses this high produces severe nausea and vomiting if introduced abruptly. Skipping or compressing escalation to "see results faster" substantially increases the probability of dehydration, electrolyte disturbance, and discontinuation. This is not a preference issue; it is a physiological one rooted in the density of GLP-1 receptors in the vagal afferent pathway and the brainstem area postrema.
How Does Retatrutide Compare to Its Real Alternatives?
| Factor | Retatrutide | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|---|
| Receptor targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Best Phase 2/3 weight loss (mean %) | ~24.2% at 48 wk (Phase 2) | ~20.9% at 72 wk (Phase 3, SURMOUNT-1) | ~14.9% at 68 wk (Phase 3, STEP-1) |
| FDA approval status | Not approved | Approved (2023) | Approved (2021) |
| Cardiovascular outcomes trial | None completed | SURMOUNT-MMO ongoing | SELECT trial positive (2023) |
| Heart rate signal | Yes (~4 bpm in Phase 2) | Modest (similar class effect) | Modest (similar class effect) |
| Evidence base quality | One Phase 2 RCT | Multiple Phase 3 RCTs | Multiple Phase 3 RCTs + outcomes data |
| Where it loses | No approval, no outcomes data, glucagon heart rate risk | No completed CV outcomes trial yet | Lower magnitude weight loss |
The honest summary: retatrutide shows impressive Phase 2 weight-loss numbers, but the evidence base is a fraction of what exists for either approved comparator. A clinician choosing between options today has more reason to trust tirzepatide or semaglutide than retatrutide.
What Did the Trial Report for Safety and Tolerability?
In Jastreboff et al. 2023, gastrointestinal events were the dominant adverse event class. Nausea, vomiting, diarrhea, and constipation occurred in a majority of participants in the higher-dose arms. Discontinuation due to adverse events was higher in the 8 mg and 12 mg groups compared to placebo, though the exact percentages varied by arm and the trial was not designed to give a precise population-level discontinuation rate.
Heart rate elevation was statistically significant in the higher-dose arms. One case of atrial fibrillation was reported, though the trial was underpowered to draw conclusions about arrhythmia risk. No cases of pancreatitis, medullary thyroid carcinoma, or serious hypoglycemia were reported, but these are rare events that require thousands of patient-years of exposure to quantify reliably. Phase 3 data will be far more informative on safety.
How to Read a Retatrutide Listing or COA Critically
Because retatrutide is not approved, any product labeled as retatrutide outside a clinical trial is not a pharmaceutical product in the regulatory sense. If you encounter a Certificate of Analysis for a research-labeled retatrutide peptide, here is what to look for and what it cannot tell you:
| COA Element | What It Means | What It Does Not Mean |
|---|---|---|
| Purity by HPLC (e.g., "98.5%") | Measured chromatographic purity at time of testing | Does not confirm correct amino acid sequence; does not rule out endotoxin or microbial contamination |
| Mass spectrometry confirmation | Molecular weight matches theoretical (useful for sequence confirmation) | Does not detect stereoisomer errors (D-amino acid substitutions) that alter receptor binding |
| Endotoxin testing (LAL) | Required for injectable safety; should be below 1 EU/mg for research use | Often absent from research-grade COAs; its absence is a meaningful red flag |
| "For research use only" | Legal disclaimer indicating no pharmaceutical approval | Does not mean the compound is safe or correctly manufactured |
The peptide sequence of retatrutide is publicly described in Eli Lilly patent filings. A supplier producing retatrutide correctly needs to synthesize a multi-receptor agonist peptide with a fatty acid side chain for half-life extension. This is a technically demanding synthesis. Errors in the fatty acid attachment point alter receptor selectivity and pharmacokinetics in ways that cannot be detected by purity alone.
What Is Known About the Phase 3 TRIUMPH Program?
Eli Lilly registered the TRIUMPH Phase 3 program for retatrutide in obesity and type 2 diabetes with ClinicalTrials.gov. As of mid-2026, detailed interim data from the Phase 3 program had not been published in a peer-reviewed journal. Enrollment criteria, exact dose arms selected for Phase 3, and primary endpoints are available on the public registry but interim efficacy and safety results are not yet in the public domain. Anyone citing specific Phase 3 percentages before a formal publication should be treated with skepticism. An NDA submission timeline has not been formally announced by Eli Lilly as of the time of writing.
Frequently Asked Questions
What doses were used in the retatrutide Phase 2 clinical trial?
The Phase 2 trial tested once-weekly subcutaneous doses of 1 mg, 4 mg, 8 mg, and 12 mg, with the 4 mg, 8 mg, and 12 mg arms using step-up escalation schedules over the first several weeks before reaching the target maintenance dose.
How much weight loss did retatrutide produce in trials?
In the 48-week Phase 2 trial, participants on the 12 mg dose lost a mean of approximately 24.2% of body weight, which was greater than tirzepatide results at comparable timepoints and among the largest reductions seen for any obesity drug in a Phase 2 study.
What is the escalation schedule for the 12 mg retatrutide dose?
Participants in the 12 mg arm began at 2 mg weekly, escalated to 4 mg, then 8 mg, before reaching 12 mg. The step-up period took approximately 20 weeks to reach maintenance dose, minimizing GI side effects.
Has retatrutide been approved by the FDA?
No. As of mid-2026, retatrutide is not FDA-approved. Phase 3 trials (TRIUMPH program) are ongoing. It remains an investigational compound.
What receptors does retatrutide target?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. The glucagon component distinguishes it from tirzepatide, which is a dual GLP-1/GIP agonist.
What were the most common side effects in retatrutide trials?
Nausea, vomiting, diarrhea, and constipation were the most commonly reported adverse events, consistent with the GLP-1 drug class. Rates were higher in higher-dose arms. Discontinuation rates due to adverse events were higher in the 8 mg and 12 mg arms compared to placebo.
How does retatrutide compare to tirzepatide in clinical data?
Phase 2 data suggest retatrutide produces greater mean weight loss (approximately 24% vs roughly 20% for tirzepatide at comparable timepoints) but these are cross-trial comparisons, not head-to-head data. Tirzepatide has Phase 3 and approval data; retatrutide does not yet.
Is retatrutide being tested for conditions other than obesity?
Yes. Phase 2 trials have examined retatrutide in type 2 diabetes and a separate trial evaluated its effects on cardiovascular risk factors. Phase 3 trials in obesity and type 2 diabetes are ongoing under the TRIUMPH program.
What does the glucagon receptor component add to retatrutide?
Glucagon receptor agonism increases hepatic glucose output and resting energy expenditure. In animal and mechanistic studies it also promotes lipolysis. The trade-off is a potential increase in heart rate and modest glycemic variability; the net clinical benefit over dual agonism remains under investigation.
Why can't I use the Phase 2 dose as a personal dosing guide?
Trial doses are research doses in a controlled setting with weekly monitoring, liver function tests, and dietary supervision. Individual tolerability, comorbidities, and drug interactions were carefully screened. Applying trial escalation schedules outside that context is medically unsupervised and carries meaningful risk.
Where is retatrutide in Phase 3 development?
Eli Lilly initiated the TRIUMPH Phase 3 program for retatrutide in obesity. Enrollment details and interim data had not been publicly reported as of the time of writing. FDA approval timelines remain speculative.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Frías JP, Dahl D, Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. The Lancet. 2023;402(10401):529-544.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232.
- ClinicalTrials.gov. TRIUMPH Phase 3 Program for Retatrutide. National Library of Medicine. Accessed 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. Accessed 2026.